Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. Senators: Bipartisan proposal to lower drug prices

Senate Finance Committee Chairman and Republican Chuck Grassley and the panel’s leading Democrat, Senator Ron Wyden, announced a bipartisan proposal to lower the Rx drug prices.

Read More »

U.S. overdose deaths post annual drop for first time in two decades

U.S. overdose deaths dropped during 2018 for the first time in nearly two decades, the CDC said, in a sign that a nationwide epidemic of drug-related deaths is abating.

Read More »

White House scraps proposal to lower U.S. drug prices

The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.

Read More »

Study Shows Hospitals Significantly Hike Drug Prices

A study commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that U.S. hospitals typically charge five times more for medications than their costs.

Read More »

U.S. Companies Continue to Pay More in Healthcare as the Cost of Drugs Keeps Rising

The United States pays more per capita for prescription drugs than any other country in the world, which is a huge concern for patients and insurance providers.

Read More »

European Commission Approves Talzenna for Patients with Inherited BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

The European Commission approved Pfizer Inc.’s Talzenna (talazoparib), an oral polypolymerase inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene 1/2-mutations who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer.

Read More »

U.S. group says Novartis MS drug price out of line with benefit

A U.S. group that reviews the value of medicines issued a critical report on Novartis’ Mayzent, calling the new multiple sclerosis drug’s $88,561 list price “far out of line” compared with the product’s benefits for patients.

Read More »

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

Merck & Co. Chief Executive Ken Frazier said a rule to base the price the U.S. government pays for some prescription drugs in Medicare on lower prices in other countries would face legal challenges if adopted.

Read More »

New Klick Health Research: Google Assistant Recognizes Medication Names Better Than Alexa and Siri

Klick Health research found Google Assistant’s comprehension of the most commonly dispensed medication names in the U.S. was, on average, almost twice as accurate as Alexa and Siri’s.

Read More »

Rituxan Superior in Rare, Deadly Skin Disease

Genentech announced positive topline results from the Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug MMF in patients with pemphigus vulgaris.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom